Le Lézard
Classified in: Health, Science and technology, Business
Subject: FNC

Workflow automation solution for post-acute care Element5 closes $30M in Series B round of funding


Second funding round led by Insight Partners in one year to drive disruption of $400B post-acute care market, accelerate market penetration of workflow automation technology in home health, hospice, skilled nursing and senior living facilities 

SAN JOSE, Calif. , May 3, 2022 /PRNewswire/ -- Element5, the world's first Automation-as-a-Service solution purpose-built for post-acute care, today announced that it has raised $30 million in a Series B funding round led by New York-based global venture capital and private equity firm Insight Partners. The new funding represents the company's second investment from Insight, who also led Element5's $15 million Series A in August 2021. The latest strategic investment is aimed at accelerating the adoption and deployment of advanced automation solutions across various service lines within the $400 billion post-acute care market.

"We're overwhelmed with the trust and support provided by Insight Partners, who share our common vision, which is to eliminate the need to perform manual, repetitive work for post-acute care," said Joe Randesi, Co-founder and CEO, Element5. "The post-acute care industry demands improvements in operational efficiency and a means to overcome chronic staffing shortages. Over the last two years, we have witnessed significant growth in the adoption of our automation technology and the next phase of our growth journey is focused on enabling more health organizations to embrace and operationalize the power of automation to reduce administrative costs and enhance patient outcomes."

Founded in 2019, Element5 uses artificial intelligence (AI)-powered robotic process automation (RPA) to deliver pre-built workflow automation solutions for post-acute care organizations. Today's ever-increasing regulatory demands continue to strain and burden teams, forcing them to spend hours manually performing administrative work. Element5's technology allows post-acute care organizations to automate their processes, eliminating highly repetitive, logic-driven administrative work. This enables teams to focus on higher-value tasks, improve operational efficiency and combat the ongoing post-acute care staffing crisis.

"After seeing the game-changing impact that Element5's innovative solution has had on the post-acute care market in such a short period of time, reinvesting was a no-brainer for Insight," said Jared Rosen, Principal, Insight Partners. "We're thrilled to have the opportunity to double down on Element5 and look forward to partnering with Joe and the team on scaling the company to the next level."

"We believe that it takes far too many clicks to complete even some of the simplest tasks in post-acute care workflows," said Eric Gordon, Co-founder and Chief Revenue Officer, Element5. "Element5 is ushering in the era of automation and post-acute care providers are witnessing tremendous value through our offerings. This round of funding is a testament to the enthusiastic demand from customers in this market."

Over the course of the last year, Element5 has gained a dominant position as an automation provider for post-acute care and was named by CB insights as a Digital Health 150 company. Leading home-health, hospice, SNF and senior living facilities trust Element5 to automate everyday processes across intake and admissions, revenue cycle management, clinical records, notifications and authorizations among a broad range of other operational tasks.

With the closing of the Series B funding round, Element5 has raised $48.5 million in total capital to date. Element5 is headquartered in San Jose, Calif., with its APAC headquarters in Chennai, India.

About Element5 
Element5 is simplifying work for post-acute care organizations by offering end-to-end workflow Automation-as-a-Service. Using artificial intelligence (AI) and robotic process automation (RPA), Element5 delivers intelligent automation and analytics that help organizations improve operational efficiency, recognize revenue faster and help their resources focus on better patient outcomes.

By automating complex administrative tasks for post-acute care, Element5 frees healthcare personnel from time-consuming and repetitive processes, empowering teams to do more, by doing less.

Built by experts with decades of experience in healthcare and post-acute care, Element5 is headquartered in San Jose, California with offices in Chennai, India. You can learn more about Element5 and RPA at www.e5.ai

About Insight Partners 
Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of February 24, 2022, the closing of the firm's recent fundraise, Fund XII, brings Insight Partners' regulatory assets under management to over $90B. Insight Partners has invested in more than 600 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has offices in London, Tel Aviv, and Palo Alto. Insight's mission is to find, fund, and work successfully with visionary executives, providing them with practical, hands-on software expertise to foster long-term success. Insight Partners meets great software leaders where they are in their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on Twitter @insightpartners.

SOURCE Element5


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: